News|Articles|July 2, 2020

Grand River Aseptic Manufacturing Opens Large-Scale Injectable Fill/Finish Facility

The new facility in Grand Rapids, MI, is part of the CDMO’s aggressive expansion plan.

US-based Grand River Aseptic Manufacturing (GRAM), a parenteral contract, development, and manufacturing organization (CDMO), has completed a $60-million expansion project in Grand Rapids, MI, and recently began occupancy at the site, the company announced in a June 30, 2020 press release.

With the expansion completed, the CDMO opened its new large-scale aseptic fill/finish facility in Grand Rapids, which more than triples its existing footprint. The added capacity, updated technologies, and state-of-the-art equipment provide flexible solutions for complex sterile injectables.

The new facility is part of the GRAM campus and is the third fill/finish facility for the company, giving it more than 100,000 ft2 of dedicated space that features:

  • A fully integrated, high-speed Bausch+Ströbel filling line

  • SKAN isolators and an IMA lyophilizer auto-loader

  • Grade C cleanroom and formulation suites.

Source: Grand River Aseptic Manufacturing


Related to this article

CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Trophy and confetti on light background, top view with space for text. Victory concept | Image Credit: ©New Africa -stock.adobe.com
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.